SPAC17G6.02c Antibody

What is SPAC17G6.02c and why is it important in fission yeast research?

SPAC17G6.02c is a protein found in Schizosaccharomyces pombe (fission yeast), identified by UniProt accession number O13780. This protein is studied as part of understanding fundamental cellular processes in fission yeast, which serves as an important model organism for eukaryotic cell biology. Antibodies against this protein enable researchers to track its expression, localization, and interactions, providing insights into its biological function. When designing experiments with this antibody, it's crucial to consider its specificity for S. pombe (strain 972 / ATCC 24843) and to establish appropriate controls to validate findings across different experimental contexts .

What are the optimal storage conditions for SPAC17G6.02c antibody?

SPAC17G6.02c antibody should be stored at -20°C or -80°C upon receipt. It's critical to avoid repeated freeze-thaw cycles as these can degrade antibody quality and reduce binding efficiency. The antibody is typically supplied in a storage buffer containing 0.03% Proclin 300 as a preservative, with 50% glycerol and 0.01M PBS at pH 7.4 as constituents. This formulation helps maintain antibody stability during storage . For long-term storage projects, consider aliquoting the antibody into smaller volumes to minimize freeze-thaw cycles. When planning experiments that span several months, it's advisable to test antibody efficiency periodically to ensure consistent performance.

What are the validated applications for SPAC17G6.02c antibody?

The SPAC17G6.02c antibody has been validated for ELISA (Enzyme-Linked Immunosorbent Assay) and WB (Western Blot) applications. These techniques are fundamental for detecting and quantifying the target protein in various experimental setups . For Western blotting, researchers should optimize protein loading, blocking conditions, and antibody dilution to achieve optimal signal-to-noise ratio. For ELISA applications, consider developing standard curves using recombinant SPAC17G6.02c protein to ensure accurate quantification. While these applications have been validated, researchers may need to optimize conditions for their specific experimental systems, particularly when working with different strains or growth conditions.

How was the SPAC17G6.02c antibody generated and purified?

The SPAC17G6.02c antibody is a polyclonal antibody raised in rabbits using recombinant Schizosaccharomyces pombe (strain 972 / ATCC 24843) SPAC17G6.02c protein as the immunogen. The antibody was purified using antigen affinity purification methods, which enhance specificity by isolating only those antibodies that bind to the target protein . This production method results in a preparation that contains multiple antibody clones recognizing different epitopes on the target protein, which can be advantageous for detection but may introduce complexity when absolute specificity is required. When interpreting results, researchers should consider potential cross-reactivity with structurally similar proteins, particularly when working with related yeast species.

How can I validate the specificity of SPAC17G6.02c antibody in my experimental system?

Validating antibody specificity requires a multi-faceted approach. First, perform Western blot analysis comparing wild-type S. pombe extracts with those from SPAC17G6.02c knockout strains (if available) to confirm absence of signal in the knockout. Second, conduct immunoprecipitation followed by mass spectrometry to identify all proteins captured by the antibody. Third, implement epitope tagging of SPAC17G6.02c (e.g., with FLAG or HA tags) and perform parallel detection with both anti-tag and anti-SPAC17G6.02c antibodies to confirm co-localization . Finally, use RNA interference to knock down SPAC17G6.02c expression and observe corresponding reduction in antibody signal.

The table below outlines a comprehensive validation protocol:

How can computational approaches enhance SPAC17G6.02c antibody research?

Biophysics-informed models can be used to predict and optimize antibody binding modes, particularly when designing variants with enhanced specificity or cross-reactivity with related proteins. These models associate each potential ligand with distinct binding modes, enabling the prediction of specific variants beyond those observed experimentally . For researchers working with SPAC17G6.02c, this approach could facilitate the development of antibodies that discriminate between closely related proteins in S. pombe or other yeast species.

Furthermore, epitope prediction algorithms can identify likely binding sites on SPAC17G6.02c, guiding the generation of synthetic peptides for more targeted antibody production. This information can also inform structural biology studies by highlighting regions of interest for crystallography or cryo-EM analysis.

What strategies can improve the reproducibility of immunoassays using SPAC17G6.02c antibody?

Improving reproducibility in SPAC17G6.02c antibody-based assays requires rigorous standardization across multiple parameters. First, establish a standardized lysate preparation protocol, controlling for yeast growth phase, media composition, and extraction methods, as protein expression and modification states can vary significantly under different conditions. Second, implement quantitative quality control measures for each antibody lot by determining affinity constants (KD values) through surface plasmon resonance or bio-layer interferometry .

For Western blot applications, develop a standard curve using recombinant SPAC17G6.02c protein at known concentrations to ensure linearity of signal detection. Additionally, incorporate internal loading controls specific for subcellular compartments where SPAC17G6.02c is expected to localize.

For immunoprecipitation experiments, standardize wash stringency and buffer composition, as these parameters significantly impact specificity. Consider using automated liquid handling systems for consistent sample processing when available. Document all experimental parameters in a detailed protocol that includes antibody dilution, incubation times/temperatures, and detection methods to facilitate reproducibility across different laboratories.

How can I optimize SPAC17G6.02c antibody for immunofluorescence applications?

Although immunofluorescence is not listed among the validated applications for the commercial SPAC17G6.02c antibody , researchers can develop and optimize this application through systematic protocol development. Begin with fixation method optimization, comparing formaldehyde, methanol, and combined fixation approaches to determine which best preserves epitope accessibility while maintaining cellular architecture. Test various permeabilization conditions (Triton X-100, saponin, or digitonin at different concentrations) to optimize antibody penetration without disrupting subcellular structures.

Antibody titration is critical; perform a dilution series (typically 1:100 to 1:2000) to identify the concentration that yields maximum specific signal with minimal background. Include blocking optimization, testing BSA, normal serum, and commercial blocking reagents at various concentrations. For signal amplification, consider tyramide signal amplification or secondary antibody multiplexing if the target protein is expressed at low levels.

Validate specificity through co-localization with tagged versions of SPAC17G6.02c or through genetic approaches (knockout/knockdown). Additionally, employ super-resolution microscopy techniques (STED, SIM, or STORM) for detailed subcellular localization studies, which may reveal previously uncharacterized distribution patterns of SPAC17G6.02c.

What are potential causes and solutions for high background in Western blots using SPAC17G6.02c antibody?

High background in Western blots using SPAC17G6.02c antibody can stem from multiple sources. Insufficient blocking is a common cause; optimize by testing different blocking agents (5% non-fat milk, 3-5% BSA, or commercial blockers) and extending blocking time to 2 hours at room temperature or overnight at 4°C. Another frequent issue is excessive antibody concentration; perform a dilution series (1:500 to 1:5000) to identify optimal concentration that maintains specific signal while reducing background .

Cross-reactivity may occur due to the polyclonal nature of the antibody; pre-adsorb the antibody with yeast lysate from SPAC17G6.02c knockout strains to remove antibodies recognizing unrelated proteins. Additionally, improper washing contributes significantly to background; implement more stringent washing (longer duration, additional washes, higher detergent concentration) while monitoring signal retention.

For persistent background issues, consider the following systematic troubleshooting approach:

How can I determine the optimal antibody concentration for different experimental applications?

Determining optimal SPAC17G6.02c antibody concentration requires systematic titration for each application. For Western blotting, prepare a serial dilution ranging from 1:250 to 1:5000 using constant protein loading. Plot signal-to-noise ratio against antibody dilution to identify the inflection point representing optimal concentration . For ELISA applications, perform a checkerboard titration of both antigen and antibody concentrations, analyzing data to identify conditions where signal is proportional to antigen concentration while maintaining acceptable background levels.

The optimization process should also consider incubation conditions. Compare overnight incubation at 4°C versus shorter incubations (1-3 hours) at room temperature, as kinetics of binding may vary with temperature. Additionally, evaluate the impact of different diluents (TBS-T with varying detergent concentrations, PBS with different carrier proteins) on specificity and sensitivity.

For quantitative applications, establish a standard curve using recombinant SPAC17G6.02c to determine the linear detection range. This is particularly important for experiments requiring quantitative comparison across multiple samples or conditions. Document all optimization parameters in a laboratory notebook to ensure reproducibility in future experiments.

How can I address epitope masking issues when using SPAC17G6.02c antibody?

Epitope masking occurs when protein-protein interactions, post-translational modifications, or conformational changes prevent antibody access to its binding site. To address this challenge with SPAC17G6.02c antibody, first identify potential masking conditions by comparing detection efficiency in native versus denaturing conditions. If the antibody performs better under denaturing conditions, this suggests conformational epitope masking .

For protein complex-related masking, consider implementing protein crosslinking followed by immunoprecipitation to capture transient interactions. Alternatively, use detergent panels of increasing strength to disrupt protein-protein interactions while maintaining SPAC17G6.02c epitope integrity. For post-translational modification-related masking, treat samples with appropriate enzymes (phosphatases, deglycosylases, etc.) prior to immunodetection to determine if modifications affect antibody binding.

When epitope masking is suspected during immunofluorescence, evaluate different epitope retrieval methods, including heat-induced epitope retrieval (citrate or EDTA buffers at varying pH) and enzymatic retrieval (proteinase K, trypsin at controlled concentrations). Document conditions that successfully unmask the epitope for future experimental planning.

How can SPAC17G6.02c antibody be adapted for high-throughput screening applications?

Adapting SPAC17G6.02c antibody for high-throughput screening requires optimization across multiple parameters. First, develop a robust automated ELISA platform using 384-well plates with optimized coating, blocking, and detection conditions. Implement liquid handling robotics for consistency across large sample sets. For increased throughput, consider adapting to homogeneous assay formats such as AlphaLISA or HTRF (Homogeneous Time-Resolved Fluorescence) that eliminate wash steps while maintaining sensitivity .

For cellular screens, develop high-content imaging workflows using the antibody in an immunofluorescence format. This approach requires optimization of fixation, permeabilization, and staining in microplate formats compatible with automated microscopy. Implement machine learning algorithms for image analysis to quantify SPAC17G6.02c levels, localization patterns, or co-localization with other markers across large sample sets.

Additionally, consider developing proximity-based assays such as in situ proximity ligation assay (PLA) to detect specific protein-protein interactions involving SPAC17G6.02c in high-throughput format. This would be particularly valuable for screening compounds that modulate such interactions. Finally, develop quality control metrics specific to high-throughput applications, including Z'-factor calculations, to ensure assay robustness across plates and experimental runs.

What are the considerations for using SPAC17G6.02c antibody in chromatin immunoprecipitation (ChIP) studies?

While SPAC17G6.02c antibody has not been specifically validated for ChIP applications , adapting it for chromatin studies requires careful optimization. Begin by determining if SPAC17G6.02c has nuclear localization or DNA-binding properties through bioinformatic analysis and cellular fractionation studies. If nuclear functions are predicted, proceed with ChIP protocol optimization.

Crosslinking conditions are critical; compare formaldehyde concentrations (0.5-2%) and incubation times (5-20 minutes) to identify optimal parameters that preserve protein-DNA interactions without creating excessive crosslinks that impede immunoprecipitation. Sonication conditions must be optimized to generate chromatin fragments of appropriate size (200-500 bp) while maintaining epitope integrity.

The immunoprecipitation step requires particular attention; test different antibody concentrations and incubation conditions, comparing results with positive control antibodies (e.g., against histones or known transcription factors). Include extensive washing steps with buffers of increasing stringency to minimize non-specific binding.

For ChIP-seq applications, library preparation and sequencing depth must be carefully considered. Perform pilot experiments with shallow sequencing to assess signal-to-noise ratio before proceeding to deeper sequencing. Validate findings through independent methods such as ChIP-qPCR at selected genomic loci. Consider investigating SPAC17G6.02c binding in different growth conditions or cell cycle stages to identify context-dependent chromatin associations.

How can computational approaches predict potential cross-reactivity of SPAC17G6.02c antibody with proteins from other organisms?

Computational prediction of SPAC17G6.02c antibody cross-reactivity involves several sophisticated approaches. Begin with sequence-based analysis by performing BLAST searches of the SPAC17G6.02c epitope region(s) against protein databases to identify proteins with significant sequence similarity across species. Use alignment algorithms that account for biochemical properties of amino acids rather than strict sequence identity, as antibodies often recognize structural motifs .

Structural bioinformatics provides another layer of analysis; use homology modeling to predict three-dimensional structures of potential cross-reactive proteins, followed by epitope mapping to assess structural similarity to SPAC17G6.02c in the epitope region. Molecular docking simulations can predict binding energy between the antibody and potential cross-reactive proteins.

Machine learning models trained on antibody cross-reactivity data can enhance prediction accuracy. These models incorporate features beyond sequence similarity, including physicochemical properties, secondary structure elements, and solvent accessibility . The table below summarizes a comprehensive cross-reactivity prediction workflow:

Experimental validation of predicted cross-reactivity is essential using Western blot or ELISA with recombinant proteins or lysates from species identified as high-risk for cross-reactivity.

What emerging technologies could enhance the utility of SPAC17G6.02c antibody in future research?

Several emerging technologies promise to expand the applications of SPAC17G6.02c antibody. Single-cell proteomics using antibody-based methods like CITE-seq (Cellular Indexing of Transcriptomes and Epitopes by Sequencing) could enable simultaneous detection of SPAC17G6.02c protein levels and transcriptome profiles in individual yeast cells. This would require conjugating the antibody to oligonucleotide barcodes and optimizing protocols for yeast cell permeabilization .

Spatial proteomics technologies like Imaging Mass Cytometry or CODEX (CO-Detection by indEXing) could reveal subcellular distribution patterns of SPAC17G6.02c with unprecedented resolution. These approaches would require metal-conjugated or DNA-barcoded versions of the antibody, respectively.

In the realm of structural biology, advances in cryo-electron tomography combined with antibody labeling could provide insights into SPAC17G6.02c localization and interactions within the native cellular context. Additionally, integrating antibody-based detection with genome editing technologies like CRISPR-Cas9 could facilitate dynamic tracking of SPAC17G6.02c in response to genetic perturbations.

For therapeutic applications in model systems, antibody engineering technologies could transform SPAC17G6.02c antibody into functionalized reagents. Techniques like bispecific antibody generation or antibody-drug conjugates could create tools for targeted manipulation of SPAC17G6.02c function in specific cellular contexts . These advanced applications would first require comprehensive characterization of antibody binding properties and optimization for the specific technological platform.